Donate

Xofigo – Designed to be Used with the Best Standard of Care Treatments

Most of the newly approved drugs and treatments for men with advanced prostate cancer are designed and approved to be used independently of other advanced prostate cancer treatments, other than with the continuation of standard androgen deprivation therapy (ADT). The newly approved drug, Xofigo, is different. It has been designed to supplement, or actually go [...]

Algeta, Completing A Successful Phase II Trial For Men With Bone Metastases Will Begin Enrolling US Survivors Into A Phase III Trial

Algeta ASA (OSE: ALGETA), has announced that it will begin to enroll US survivors into its Alsympca phase III trial evaluating Alpharadin (radium-223). Alpharadin is designed to be used as a treatment for bone metastases in prostate cancer survivors with hormone-refractory prostate cancer (HRPC). The announcement of the trial follows a successful end-of-phase II meeting [...]

Go to Top